Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation
Aoli Wang(Chinese Academy of Sciences), Qingsong Liu(University of Science and Technology of China)
Cited by 47
Related Papers
Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells
|Oncotarget|2015|46
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway
|Acta Pharmacologica Sinica|2020|33
Hydroxychloroquine facilitates autophagosome formation but not degradation to suppress the proliferation of cervical cancer SiHa cells
|Oncology Letters|2014|30
Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy
|Acta Pharmaceutica Sinica B|2023|25